Related stories
Amtagvi Sales Reach $102M, Up 77%
M impact | EARNINGS | Nov 16, 2026, 08:03 AM UTC
Iovance Biotherapeutics Reports Third-Quarter Revenue of $121.47 Million
Third-quarter revenue increased 80% year over year, while net loss narrowed 76%. Higher Amtagvi infusions, corresponding Proleukin sales and price increases drove revenue growth; l
M impact | EQUITY | Nov 05, 2026, 02:21 PM UTC
Iovance Biotherapeutics reports Q3 revenue of $121.5 million
Iovance reported Q3 revenue of $121.5 million, versus a FactSet estimate of $116.0 million.
M impact | EQUITY | Nov 05, 2026, 12:33 PM UTC
Iovance Expects 2026 Product Revenue of $410M to $420M
M impact | EARNINGS | Nov 05, 2026, 12:21 PM UTC
Iovance Reports Third-Quarter 2026 Revenue of About $122 Million
Iovance said total revenue increased about 80% year over year and U.S. Amtagvi revenue rose about 77%.
M impact | EQUITY | Nov 05, 2026, 12:19 PM UTC
Iovance Biotherapeutics Posts Q3 Loss of $0.05 a Share
Iovance reported a Q3 loss of $0.05 per share, versus the FactSet estimate of a $0.08 loss.
M impact | EQUITY | Nov 05, 2026, 12:16 PM UTC